Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?

Author:

Mangum Blake R.,Pogue Jason M.,Barber Katie E.

Abstract

Abstract Purpose of Review Antimicrobial resistance is a growing threat to public health, leading to millions of antibiotic-resistant infections and thousands of deaths annually in the USA. One concerning issue is the rise of extended-spectrum beta-lactamase (ESBL)–producing Enterobacterales. Current treatments often involve intravenous carbapenems, leading to prolonged hospital stays and financial burdens. Recent Findings To address this, new oral penem agents, tebipenem and sulopenem, are being investigated. They are administered as prodrugs, enhancing bioavailability before becoming active in the gastrointestinal tract, potentially treating multidrug-resistant infections in outpatient settings. Despite promise in clinical trials, challenges exist, such as tebipenem’s renal excretion, requiring dose adjustments for kidney dysfunction. Additionally, sulopenem failed noninferiority margins in trials, and neither drug has established susceptibility testing standards. Summary Tebipenem and sulopenem offer potential oral solutions for antimicrobial resistance, especially in urinary tract infections, but further research is needed for optimal dosing and susceptibility testing.

Publisher

Springer Science and Business Media LLC

Reference34 articles.

1. CDC. Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention. National Center for Emerging Zoonotic and Infectious Diseases (U.S.). 2019. https://doi.org/10.15620/cdc:82532.

2. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases Society of America 2023 Guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. 2023. https://doi.org/10.1093/cid/ciad428.

3. Kassakian SZ, Mermel LA. Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. Antimicrob Resist Infect Control. 2014;3(1):9. https://doi.org/10.1186/2047-2994-3-9.

4. Fluoroquinolone-resistant E.coli. Centers for Disease Control and Prevention. Antibiotic Resistance.A.R. & Patient Safety Portal. Antibiotic resistance and patient safety portal. Accessed October 26, 2023. https://arpsp.cdc.gov/profile/antibiotic-resistance?tab=antibiotic-resistance.

5. Hospital adjusted expenses per inpatient day | KFF. Accessed August 2, 2023. https://www.kff.org/health-costs/state-indicator/expenses-per-inpatient-day/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3